CD8A and neoplasm: Together, these results show that disrupting MCJ expression in CD8 cells improves the efficacy of adoptive TCR-specific CD8 cell therapy on the treatment of solid tumors, by facilitating the accumulation of tumor-infiltrating transferred CD8 cells as well as boosting their effector function.